Skip to content

miRNA in Patients With Thoracic, Abdominal and Intracranial Aneurysms

miRNA in Patients With Thoracic, Abdominal and Intracranial Aneurysms

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05382611
Acronym
miRNA
Enrollment
35
Registered
2022-05-19
Start date
2018-05-19
Completion date
2021-12-31
Last updated
2022-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Aneurysm

Keywords

miRNA

Brief summary

To assess the expression of miRNA in patients with TAA, AAA in aneurysmatic tissue and to compare this expression with the healthy tissue in the same patient. In the same cohort, to asses the presence of miRNA in plasma and to compare with the control group. Over the period of three years,to follow subjects in order to assess if the presence of certain miRNAs speeds up or slows down the progression of disease. In patients with intracranial aneurysms to detect miRNA in plasma especially in patients with familial occurrence.

Detailed description

MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. Acting at the post-transcriptional level, MicroRNAs have been shown to be involved in a wide range of biological processes such as cell cycle control, apoptosis and several developmental and physiological processes including stem cell differentiation, hematopoiesis, hypoxia, cardiac and skeletal muscle development. In addition to their important roles in healthy individuals, microRNAs have also been implicated in a number of diseases including a broad range of cancers, cardiovascular and heart disease. Their different expression in aortic tissue in patients with aortic abdominal aneurysm and their association with the progression of the disease were confirmed. They represent the potential target for the treatment of the disease. MiRNA act as biomarkers showing the potential risk of the presence of TAA, AAA and intracranial aneurysm, for the prediction of TAA and AAA progression and for the discovery of new treatment possibilities.

Interventions

DIAGNOSTIC_TESTngs next generation sequencing

the samples from aneurysmatic tissue and healthy aortic tissue will be investigated using NGS

Sponsors

Czech Academy of Sciences
CollaboratorOTHER
Na Homolce Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

1. 18 years of age or older 2. Patient willing and able to sign clinical trial Informed Consent 3. Patient with AAA or TAA who require an open surgical procedure, or patient with intracranial aneurysm indicated for radiological intervention

Exclusion criteria

1\. Patient with multiorgan failure

Design outcomes

Primary

MeasureTime frameDescription
The comparison of miRNA in healthy and aneurysmatic tissue2020 at end of trialmiRNA will be compared in blood and in healthy and aneurysmatic tissue using ngs

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026